Urethritis screening: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
m (Bot: Removing from Primary care)
 
(24 intermediate revisions by 6 users not shown)
Line 4: Line 4:


==Overview==
==Overview==
High-risk individuals in specific conditions needs to be screened for [[sexually transmitted diseases]]. The U.S. Preventive Service Task Force ([[USPSTF]]) developed recommendations for this screening.
High-risk individuals should be screened for [[sexually transmitted diseases]]. The U.S. Preventive Service Task Force ([[USPSTF]]) developed recommendations for the screening of for [[Chlamydia trachomatis|''Chlamydia trachomatis'']] and [[N. gonorrhea|''N. gonorrhea'']].


==Screening==
==Screening==
According to the U.S. Preventive Service Task Force (USPSTF), screening for sexually transmitted disease is recommended as outlines below for [[Chlamydia Trachomatis]] and '''''N. Gonorrhea'''''<ref name=USPSTF> Screening recommendation for chlamydia. UPSTF. http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/chlamydia-and-gonorrhea-screening?ds=1&s=chlamydia(2014). Acessed on September 28, 2016</ref><ref name=cde>US preventive services task forces. Gonorrhea and chlamydia screening (2014) https://www.uspreventiveservicestaskforce.org/Page/Document/ClinicalSummaryFinal/chlamydia-and-gonorrhea-screening Accessed on September 28, 2016</ref>.
According to the U.S. Preventive Service Task Force ([[USPSTF]]), screening for sexually transmitted disease is recommended as outlined below for [[Chlamydia trachomatis]] and [[N. gonorrhea]].<ref name="USPSTF">Screening recommendation for chlamydia. UPSTF. http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/chlamydia-and-gonorrhea-screening?ds=1&s=chlamydia(2014). Acessed on September 28, 2016</ref><ref name="cde">US preventive services task forces. Gonorrhea and chlamydia screening (2014) https://www.uspreventiveservicestaskforce.org/Page/Document/ClinicalSummaryFinal/chlamydia-and-gonorrhea-screening Accessed on September 28, 2016</ref>


 
{| style="border: 0px; margin: 3px;" align="center"
===Chlamydia Trachomatis===
! colspan="2" style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF|Chlamydia trachomatis}}
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center
|-
|+
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF|Population}}
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF|Population}}
! style="background: #4479BA; width: 500px;" | {{fontcolor|#FFF|Recommendations}}
! style="background: #4479BA; width: 500px;" | {{fontcolor|#FFF|Recommendations}}
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" | '''Women'''
| style="padding: 5px 5px; background: #DCDCDC;" | '''Women'''
| style="padding: 5px 5px; background: #FFFFE0;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Sexually active women under 25 years of age
* Sexually active women under 25 years of age
* Sexually active women age 25 years and older if at increased risk
* Sexually active women aged 25 years and older if at increased risk
**Prior history of sexually transmitted infection
**Prior history of sexually transmitted infection
**A new sex partner
**A new sex partner
**More than one sex partner
**More than one sex partner
**A sex partner with concurrent partners
**A sex partner with concurrent partners
**A sex partner who has a sexually transmitted infection
**A sex partner who has a [[sexually transmitted infection]]
* Retest 3 months after treatment.
*Retest 3 months after treatment.
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" | '''Men'''
| style="padding: 5px 5px; background: #DCDCDC;" | '''Men'''
| style="padding: 5px 5px; background: #FFFFE0;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Consider screening young men in high prevalence clinical settings or in populations with high burden of infection(e.g.Men who have sex with men)
*Consider screening young men in high-prevalence clinical settings or in populations with a high burden of infection (e.g., men who have sex with men)
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" | '''Pregnant women'''
| style="padding: 5px 5px; background: #DCDCDC;" | '''Pregnant women'''
| style="padding: 5px 5px; background: #FFFFE0;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*All pregnant women under 25 years of age
*All pregnant women under 25 years of age
*Pregnant women, aged 25 and older if at increased risk
*Pregnant women aged 25 years and older if at increased risk
*Retest during the 3rd trimester for women under 25 years of age or at risk
*Retest during the [[third trimester]] for women under 25 years of age or at risk
*Pregnant women with chlamydial infection should have a test-of-cure 3-4 weeks after treatment and be retested within 3 months
*Pregnant women with chlamydial infection should have a test-of-cure 3-4 weeks after treatment and be retested within 3 months
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" | '''Men Who have Sex With Men (MSM)
| style="padding: 5px 5px; background: #DCDCDC;" | '''Men Who have Sex With Men (MSM)'''
| style="padding: 5px 5px; background: #FFFFE0;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*At least annually for sexually active MSM at sites of contact (urethra, rectum) regardless of condom use
*At least annually for sexually active MSM at sites of contact (urethra, rectum) regardless of condom use
*Every 3 to 6 months if at increased risk
*Every 3 to 6 months if at increased risk
|-
|-
| style="padding: 5px 5px; background: #DCDCDC;" | '''HIV positive patients'''
| style="padding: 5px 5px; background: #DCDCDC;" | '''HIV positive patients'''
| style="padding: 5px 5px; background: #FFFFE0;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* For sexually active individuals, screen at first HIV evaluation, and at least annually  
* For sexually active individuals, screen at first [[HIV]] evaluation and at least annually  
* More frequent screening may be indicated depending on individual risk behaviors and the local epidemiology
* More frequent screening may be indicated depending on individual risk behaviors and local epidemiology
|}
|}


===Neisseria Gonorrhea===
{| style="border: 0px; margin: 3px;" align="center"
 
! colspan="2" style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF|Neisseria Gonorrhea}}
{| style="border: 0px; font-size: 90%; margin: 3px;" align=center
|-
|+
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF|Population}}
! style="background: #4479BA; width: 150px;" | {{fontcolor|#FFF|Population}}
! style="background: #4479BA; width: 500px;" | {{fontcolor|#FFF|Recommendations}}
! style="background: #4479BA; width: 500px;" | {{fontcolor|#FFF|Recommendations}}
Line 60: Line 58:
* Sexually active women under 25 years of age
* Sexually active women under 25 years of age
* Sexually active women age 25 years and older if at increased risk
* Sexually active women age 25 years and older if at increased risk
**Prior history of sexually transmitted infection
**Prior history of [[sexually transmitted infection]]
**A new sex partner
**A new sex partner
**More than one sex partner
**More than one sex partner
**A sex partner with concurrent partners
**A sex partner with concurrent partners
**A sex partner who has a sexually transmitted infection
**A sex partner who has a [[sexually transmitted infection]]
* Retest 3 months after treatment.
* Retest 3 months after treatment.
|-
|-
Line 79: Line 77:
| style="padding: 5px 5px; background: #DCDCDC;" | '''HIV positive patients'''
| style="padding: 5px 5px; background: #DCDCDC;" | '''HIV positive patients'''
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* For sexually active individuals, screen at first HIV evaluation, and at least annually  
* For sexually active individuals, screen at first [[HIV]] evaluation and at least annually  
* More frequent screening may be indicated depending on individual risk behaviors and the local epidemiology
* More frequent screening may be indicated depending on individual risk behaviors and the local epidemiology
|}
|}
Line 86: Line 84:
{{Reflist|2}}
{{Reflist|2}}


 
[[Category:Medicine]]
[[Category:Emergency medicine]]
[[Category:Up-To-Date]]
[[Category:Infectious disease]]
[[Category:Infectious disease]]
[[Category:Primary care]]
[[Category:Urology]]
 
[[Category:Nephrology]]
{{WH}}
{{WS}}

Latest revision as of 00:36, 30 July 2020

Urinary Tract Infections Main Page

Sexually Transmitted Diseases Main Page

Urethritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Urethritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Urethritis screening On the Web

Most recent articles

Most cited articles

Review articles

Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Urethritis screening

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA onUrethritis screening

CDC onUrethritis screening

Urethritis screeningin the news

Blogs onUrethritis screening

Directions to Hospitals Treating Urethritis

Risk calculators and risk factors for Urethritis screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2]

Overview

High-risk individuals should be screened for sexually transmitted diseases. The U.S. Preventive Service Task Force (USPSTF) developed recommendations for the screening of for Chlamydia trachomatis and N. gonorrhea.

Screening

According to the U.S. Preventive Service Task Force (USPSTF), screening for sexually transmitted disease is recommended as outlined below for Chlamydia trachomatis and N. gonorrhea.[1][2]

Chlamydia trachomatis
Population Recommendations
Women
  • Sexually active women under 25 years of age
  • Sexually active women aged 25 years and older if at increased risk
    • Prior history of sexually transmitted infection
    • A new sex partner
    • More than one sex partner
    • A sex partner with concurrent partners
    • A sex partner who has a sexually transmitted infection
  • Retest 3 months after treatment.
Men
  • Consider screening young men in high-prevalence clinical settings or in populations with a high burden of infection (e.g., men who have sex with men)
Pregnant women
  • All pregnant women under 25 years of age
  • Pregnant women aged 25 years and older if at increased risk
  • Retest during the third trimester for women under 25 years of age or at risk
  • Pregnant women with chlamydial infection should have a test-of-cure 3-4 weeks after treatment and be retested within 3 months
Men Who have Sex With Men (MSM)
  • At least annually for sexually active MSM at sites of contact (urethra, rectum) regardless of condom use
  • Every 3 to 6 months if at increased risk
HIV positive patients
  • For sexually active individuals, screen at first HIV evaluation and at least annually
  • More frequent screening may be indicated depending on individual risk behaviors and local epidemiology
Neisseria Gonorrhea
Population Recommendations
Women
  • Sexually active women under 25 years of age
  • Sexually active women age 25 years and older if at increased risk
  • Retest 3 months after treatment.
Men Who have Sex With Men (MSM)
  • At least annually for sexually active MSM at sites of contact (urethra, rectum, pharynx) regardless of condom use
  • Every 3 to 6 months if at increased risk
Pregnant women
  • All pregnant women under 25 years of age and older women if at increased risk
  • Retest 3 months after treatment
HIV positive patients
  • For sexually active individuals, screen at first HIV evaluation and at least annually
  • More frequent screening may be indicated depending on individual risk behaviors and the local epidemiology

References

  1. ↑ Screening recommendation for chlamydia. UPSTF. http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/chlamydia-and-gonorrhea-screening?ds=1&s=chlamydia(2014). Acessed on September 28, 2016
  2. ↑ US preventive services task forces. Gonorrhea and chlamydia screening (2014) https://www.uspreventiveservicestaskforce.org/Page/Document/ClinicalSummaryFinal/chlamydia-and-gonorrhea-screening Accessed on September 28, 2016
Retrieved from "https://www.wikidoc.org/index.php?title=Urethritis_screening&oldid=1644358"